Mathematical models for translational and clinical oncology

Journal of Clinical Bioinformatics

Volumn 3, Issue 1, 2013, Pages

  Gallasch, Ralf ^a   Efremova, Mirjana ^a   Charoentong, Pornpimol ^a   Hackl, Hubert ^a   Trajanoski, Zlatko ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896379970     PISSN: None     EISSN: 20439113     Source Type: Journal    
DOI: 10.1186/2043-9113-3-23     Document Type: Review

References (88)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013, 339:1546-1558. 10.1126/science.1235122, 3749880, 23539594.
2. Pabinger S, Dander A, Fischer M, Snajder R, Sperk M, Efremova M, Krabichler B, Speicher MR, Zschocke J, Trajanoski Z. A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform 2013,
3. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823. 10.1073/pnas.68.4.820, 389051, 5279523.
4. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194:23-28. 10.1126/science.959840, 959840.
5. Swierniak A, Kimmel M, Smieja J. Mathematical modeling as a tool for planning anticancer therapy. Eur J Pharmacol 2009, 625:108-121. 10.1016/j.ejphar.2009.08.041, 2813310, 19825370.
6. Lowengrub JS, Frieboes HB, Jin F, Chuang Y-L, Li X, Macklin P, Wise SM, Cristini V. Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity 2010, 23:R1-R9. 10.1088/0951-7715/23/1/R01, 2929802, 20808719.
7. Byrne HM, Alarcon T, Owen MR, Webb SD, Maini PK. Modelling aspects of cancer dynamics: a review. Philos Transact A Math Phys Eng Sci 2006, 364:1563-1578.
8. Deisboeck TS, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. Annu Rev Biomed Eng 2011, 13:127-155. 10.1146/annurev-bioeng-071910-124729, 21529163.
9. Stransky B, de Souza SJ. Modeling tumor evolutionary dynamics. Front Physiol 2012, 3:480. 3572685, 23420281.
10. Fisher JC, Hollomon JH. A hypothesis for the origin of cancer foci. Cancer 1951, 4:916-918. 10.1002/1097-0142(195109)4:5<916::AID-CNCR2820040504>3.0.CO;2-7, 14879355.
11. Nordling CO. A new theory on cancer-inducing mechanism. Br J Cancer 1953, 7:68-72. 10.1038/bjc.1953.8, 2007872, 13051507.
12. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954, 8:1-12. 10.1038/bjc.1954.1, 2007940, 13172380.
13. Ashley DJ. The two "hit" and multiple "hit" theories of carcinogenesis. Br J Cancer 1969, 23:313-328. 10.1038/bjc.1969.41, 2008269, 5788039.
14. Moolgavkar SH, Knudson AG. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981, 66:1037-1052.
15. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A 2002, 99:15095-15100. 10.1073/pnas.222118199, 137549, 12415112.
16. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res 2003, 63:6212-6220.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
18. Greenspan H. Models for the growth of a solid tumor by diffusion. Stud Appl Math 1972, 52:317-340.
19. McElwain DLS, Ponzo PJ. A model for the growth of a solid tumor with non-uniform oxygen consumption. Math Biosci 1977, 35:267-279.
20. Greenspan HP. On the growth and stability of cell cultures and solid tumors. J Theor Biol 1976, 56:229-242. 10.1016/S0022-5193(76)80054-9, 1263527.
21. Byrne HM, Chaplain MAJ. Modelling the role of cell-cell adhesion in the growth and development of carcinomas. Math Comput Model 1996, 24:1-17.
22. Balding D, McElwain DL. A mathematical model of tumour-induced capillary growth. J Theor Biol 1985, 114:53-73. 10.1016/S0022-5193(85)80255-1, 2409405.
23. Byrne HM, Chaplain MA. Mathematical models for tumour angiogenesis: numerical simulations and nonlinear wave solutions. Bull Math Biol 1995, 57:461-486.
24. Chaplain MA. Mathematical modelling of angiogenesis. J Neurooncol 2000, 50:37-51. 10.1023/A:1006446020377, 11245280.
25. Chaplain MA, Stuart AM. A model mechanism for the chemotactic response of endothelial cells to tumour angiogenesis factor. IMA J Math Appl Med Biol 1993, 10:149-168. 10.1093/imammb/10.3.149, 8263357.
26. Levine HA, Pamuk S, Sleeman BD, Nilsen-Hamilton M. Mathematical modeling of capillary formation and development in tumor angiogenesis: penetration into the stroma. Bull Math Biol 2001, 63:801-863. 10.1006/bulm.2001.0240, 11565406.
27. Anderson AR, Chaplain MA. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol 1998, 60:857-899. 10.1006/bulm.1998.0042, 9739618.
28. Mantzaris NV, Webb S, Othmer HG. Mathematical modeling of tumor-induced angiogenesis. J Math Biol 2004, 49:111-187.
29. McDougall SR, Anderson ARA, Chaplain MAJ, Sherratt JA. Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies. Bull Math Biol 2002, 64:673-702. 10.1006/bulm.2002.0293, 12216417.
30. Stéphanou A, McDougall SR, Anderson ARA, Chaplain MAJ. Mathematical modelling of the influence of blood rheological properties upon adaptative tumour-induced angiogenesis. Math Comput Model 2006, 44:96-123.
31. Stéphanou A, McDougall SR, Anderson ARA, Chaplain MAJ. Mathematical modelling of flow in 2D and 3D vascular networks: applications to anti-angiogenic and chemotherapeutic drug strategies. Math Comput Model 2005, 41:1137-1156.
32. D' Onofrio A, Gandolfi A. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). Math Biosci 2004, 191:159-184. 10.1016/j.mbs.2004.06.003, 15363652.
33. Ledzewicz U, Schaettler H. Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J Control Optim 2007, 46(3):1052-1079.
34. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999, 59:4770-4775.
35. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6:924-935. 10.1038/nrc2013, 17109012.
36. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012, 481:306-313. 10.1038/nature10762, 3367003, 22258609.
37. Haeno H, Iwasa Y, Michor F. The evolution of two mutations during clonal expansion. Genetics 2007, 177:2209-2221. 10.1534/genetics.107.078915, 2219486, 18073428.
38. Nowak MA, Michor F, Komarova NL, Iwasa Y. Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A 2004, 101:10635-10638. 10.1073/pnas.0400747101, 489986, 15252197.
39. Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N. The temporal order of genetic and pathway alterations in tumorigenesis. PLoS One 2011, 6:e27136. 10.1371/journal.pone.0027136, 3206070, 22069497.
40. Durrett R, Schmidt D, Schweinsberg J. A waiting time problem arising from the study of multi-stage carcinogenesis. Ann Appl Probab 2009, 19:676-718.
41. Attolini CS-O, Michor F. Evolutionary theory of cancer. Ann N Y Acad Sci 2009, 1168:23-51. 10.1111/j.1749-6632.2009.04880.x, 19566702.
42. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007, 3:e225. 10.1371/journal.pcbi.0030225, 2065895, 17997597.
43. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 2010, 107:18545-18550. 10.1073/pnas.1010978107, 2972991, 20876136.
44. Quaranta V, Rejniak KA, Gerlee P, Anderson ARA. Invasion emerges from cancer cell adaptation to competitive microenvironments: quantitative predictions from multiscale mathematical models. Semin Cancer Biol 2008, 18:338-348. 10.1016/j.semcancer.2008.03.018, 3789515, 18524624.
45. Lee H-O, Silva AS, Concilio S, Li Y-S, Slifker M, Gatenby RA, Cheng JD. Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res 2011, 71:6327-6337. 10.1158/0008-5472.CAN-11-0304, 3197231, 21859828.
46. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8:56-61. 10.1038/nrc2255, 18059462.
47. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1733.
48. Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Curr Pharm Des 2006, 12:261-271. 10.2174/138161206775201956, 16454743.
49. Komarova N. Stochastic modeling of drug resistance in cancer. J Theor Biol 2006, 239:351-366. 10.1016/j.jtbi.2005.08.003, 16194548.
50. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 2005, 102:9714-9719. 10.1073/pnas.0501870102, 1172248, 15980154.
51. Basanta D, Gatenby RA, Anderson ARA. Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm 2012, 9:914-921. 10.1021/mp200458e, 3325107, 22369188.
52. Swierniak A, Smieja J. Analysis and optimization of drug resistant and phase-specific cancer chemotherapy models. Math Biosci Eng MBE 2005, 2:657-670.
53. Kimmel M, Axelrod DE. Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. Genetics 1990, 125:633-644. 1204089, 2379824.
54. Kimmel M, Swierniak A, Polanski A. Infinite-dimensional model of evolution of drug resistance of cancer cells. J Math Syst Estim Contr 1998, 8(1):1-16.
55. Smieja J, Swierniak A. Different models of chemotherapy taking into account drug resistance stemming from gene amplification. Int. J. Appl Math Comp Sci 2003, 13.3:297-306.
56. Harnevo LE, Agur Z. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother Pharmacol 1992, 30:469-476. 10.1007/BF00685599, 1394803.
57. Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol 2009, 5:e1000557. 10.1371/journal.pcbi.1000557, 2766072, 19893626.
58. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540. 3436069, 22722843.
59. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA, Vogelstein B, Nowak MA. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013, 2:e00747. 10.7554/eLife.00747, 3691570, 23805382.
60. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297. 10.1038/nature03095, 15549090.
61. Fister KR, Panetta JC. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J Appl Math 2000, 60:1059-1072.
62. Byrne HM, Owen MR, Alarcon T, Murphy J, Maini PK. Modelling the response of vascular tumours to chemotherapy: a multiscale approach. Math Models Methods Appl Sci 2006, 16:1219-1241.
63. De Pillis LG, Gu W, Radunskaya AE. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J Theor Biol 2006, 238:841-862. 10.1016/j.jtbi.2005.06.037, 16153659.
64. De Pillis L, Radunskaya A. A mathematical model of immune response to tumor invasion. Proc Second MIT Conf Comput Fluid Solid Mech KJ Bathe Ed Fluid Solid Mech 2003, Comput: Solid.
65. Jackson TL, Byrne HM. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci 2000, 164:17-38. 10.1016/S0025-5564(99)00062-0, 10704636.
66. Panetta JC, Adam J. A mathematical model of cycle-specific chemotherapy. Math Comput Model 1995, 22:67-82.
67. Powathil GG, Adamson DJA, Chaplain MAJ. Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model. PLoS Comput Biol 2013, 9:e1003120. 10.1371/journal.pcbi.1003120, 3708873, 23874170.
68. Powathil G, Kohandel M, Sivaloganathan S, Oza A, Milosevic M. Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy. Phys Med Biol 2007, 52:3291-3306. 10.1088/0031-9155/52/11/023, 17505103.
69. Powathil GG, Gordon KE, Hill LA, Chaplain MAJ. Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. J Theor Biol 2012, 308:1-19.
70. Cojocaru L, Agur Z. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math Biosci 1992, 109:85-97. 10.1016/0025-5564(92)90053-Y, 1591451.
71. Bozic I, Allen B, Nowak MA. Dynamics of targeted cancer therapy. Trends Mol Med 2012, 18:311-316. 10.1016/j.molmed.2012.04.006, 3372676, 22595628.
72. Billy F, Ribba B, Saut O, Morre-Trouilhet H, Colin T, Bresch D, Boissel J-P, Grenier E, Flandrois J-P. A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. J Theor Biol 2009, 260:545-562. 10.1016/j.jtbi.2009.06.026, 19615383.
73. Kirschner DE, Jackson TL, Arciero JC. A mathematical model of tumor-immune evasion and siRNA treatment. Discrete Contin Dyn Syst - Ser B 2003, 4:39-58.
74. Dewanji A, Luebeck EG, Moolgavkar SH. A generalized Luria-Delbrück model. Math Biosci 2005, 197:140-152. 10.1016/j.mbs.2005.07.003, 16137718.
75. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother CII 2008, 57:425-439.
76. Nanda S, Moore H, Lenhart S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 2007, 210:143-156. 10.1016/j.mbs.2007.05.003, 17599363.
77. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003, 63:1317-1324.
78. Mok W, Stylianopoulos T, Boucher Y, Jain RK. Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin Cancer Res Off J Am Assoc Cancer Res 2009, 15:2352-2360.
79. Rockne R, Alvord EC, Rockhill JK, Swanson KR. A mathematical model for brain tumor response to radiation therapy. J Math Biol 2008, 58:561-578. 3784027, 18815786.
80. Richard M, Kirkby KJ, Webb RP, Kirkby NF. A mathematical model of response of cells to radiation. Nucl Instruments Methods Phys Res Sect B Beam Interactions Mater Atoms 2007, 255:18-22.
81. Enderling H, Anderson ARA, Chaplain MAJ. A model of breast carcinogenesis and recurrence after radiotherapy. PAMM 2007, 7:1121701-1121702.
82. De Boer RJ, Hogeweg P, Dullens HF, De Weger RA, Den Otter W. Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical mode. J Immunol Baltim Md 1950 1985, 134:2748-2758.
83. Matzavinos A, Chaplain MAJ, Kuznetsov VA. Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. Math Med Biol J IMA 2004, 21:1-34.
84. Kirschner D, Panetta JC. Modeling immunotherapy of the tumor-immune interaction. J Math Biol 1998, 37:235-252. 10.1007/s002850050127, 9785481.
85. De Pillis LG, Radunskaya AE, Wiseman CL. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 2005, 65:7950-7958.
86. Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, Breban R. BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. PLoS One 2013, 8:e56327. 10.1371/journal.pone.0056327, 3581521, 23451041.
87. Wei H-C. A numerical study of a mathematical model of pulsed immunotherapy for superficial bladder cancer. Jpn J Ind Appl Math 2013, 30:441-452.
88. Rihan FA, Safan M, Abdeen MA, Abdel Rahman D. Qualitative and computational analysis of a mathematical model for tumor-immune interactions. J Appl Math 2012, Article ID 475720:19.